Cancer is the second leading cause of death in the US. It has been estimated that approximately one-half of all men and one-third of all women will develop some form of cancer during their lifetimes. An improved understanding of the genetics of cancer may enable the development of novel therapeutics and diagnostic tests for cancer, as well as better targeting of cancer treatments to responsive patient populations.
“We look forward to applying Perlegen’s expertise to further our understanding of the important role genetics plays in cancer,” said Dr David Cox, chief scientific officer of Perlegen. “We are proud to collaborate with Genentech, a recognized leader in oncology therapeutics and pioneer in targeted therapies for cancer patients.”
Terms of the agreement were not disclosed.